Inquire About Our Ongoing Clinical Trials - Call Us Today!!
  
   


 

Research Study Summary

TTP488-301: Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

Purpose:

Do you qualify for the STEADFAST study?
To qualify for the STEADFAST study you must be 50 years of Age or older with a confirmed diagnosis of mile Alzheimer's disease. You must already be taking one or more of the following medications for at least 3 months prior to the study:

· Memantine

· Gelantemine

· Aricept

· Exelon

You must have a caregiver who is also willing to be a part of the STEADFAST clinical trial. Your caregiver will need to attend study visits with you and answer questions about your disease.

ELIGIBILITY CRITERIA:

· Diagnosis of probable AD, consistent with the criteria from the 2011 National Institute on Aging and the Alzheimer's Association workgroup (McKhann et al., 2011). Evidence of progression needs to be documented in source documentation at the time of screening based on review of prior medical records

· Mini-Mental State Exam (MMSE) score of 21-26 inclusive at screening

· CDR global score of 0.5 or 1 at screening

· Rosen-Modified Hachinski Ischemia Score ≤4 at screening


BackBack to top
 
© CNS Research, Inc.                                                                                                       Contact: (800) 707-6013 Email: info@cns-research.com